{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T23:32:58Z","timestamp":1791761578221,"version":"4.3.4"},"reference-count":35,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T00:00:00Z","timestamp":1468886400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Infection of the stomach by the gastric pathogen <ns4:italic>Helicobacter pylori<\/ns4:italic> results in chronic active gastritis and leads to the development of gastric and duodenal ulcer disease and gastric adenocarcinoma. Eradication of <ns4:italic>H. pylori<\/ns4:italic> infection improves or resolves the associated pathology. Current treatments of <ns4:italic>H. pylori<\/ns4:italic> infection rely on acid suppression in combination with at least two antibiotics. The role of acid suppression in eradication therapy has been variously attributed to antibacterial activity of proton pump inhibitors directly or through inhibition of urease activity or increased stability and activity of antibiotics. Here we discuss the effect of acid suppression on enhanced replicative capacity of <ns4:italic>H. pylori<\/ns4:italic> to permit the bactericidal activity of growth-dependent antibiotics. The future of eradication therapy will rely on improvement of acid inhibition along with current antibiotics or the development of novel compounds targeting the organism\u2019s ability to survive in acid.<\/ns4:p>","DOI":"10.12688\/f1000research.8598.1","type":"journal-article","created":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T15:35:05Z","timestamp":1468942505000},"page":"1747","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":72,"title":["The role of acid inhibition in Helicobacter pylori eradication"],"prefix":"10.12688","volume":"5","author":[{"given":"David R.","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2016,7,19]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003840.pub5","article-title":"Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people.","volume":"4","author":"A Ford","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"ref-2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004062.pub2","article-title":"H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer.","author":"J Gisbert","year":"2004","journal-title":"Cochrane Database Syst Rev."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"1949-58","DOI":"10.1046\/j.1365-2036.2001.01109.x","article-title":"A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer.","volume":"15","author":"A Leodolter","year":"2001","journal-title":"Aliment Pharmacol Ther."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"1345-53","DOI":"10.1093\/jnci\/dji277","article-title":"Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma.","volume":"97","author":"L Chen","year":"2005","journal-title":"J Natl Cancer Inst."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"1086-93","DOI":"10.1093\/annonc\/mdn760","article-title":"Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type.","volume":"20","author":"A Stathis","year":"2009","journal-title":"Ann Oncol."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"575-7","DOI":"10.1016\/0140-6736(93)91409-F","article-title":"Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori.","volume":"342","author":"A Wotherspoon","year":"1993","journal-title":"Lancet."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"275-8","DOI":"10.1111\/j.1523-5378.2007.00518.x","article-title":"A report card to grade Helicobacter pylori therapy.","volume":"12","author":"D Graham","year":"2007","journal-title":"Helicobacter."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"183-98","DOI":"10.4292\/wjgpt.v6.i4.183","article-title":"Antibiotic treatment for Helicobacter pylori: Is the end coming?","volume":"6","author":"S Kim","year":"2015","journal-title":"World J Gastrointest Pharmacol Ther."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"490-6","DOI":"10.1128\/AAC.35.3.490","article-title":"Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.","volume":"35","author":"T Iwahi","year":"1991","journal-title":"Antimicrob Agents Chemother."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"769-74","DOI":"10.1128\/AAC.37.4.769","article-title":"Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells.","volume":"37","author":"K Nagata","year":"1993","journal-title":"Antimicrob Agents Chemother."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"1573-8","DOI":"10.1016\/0016-5085(94)90121-X","article-title":"The proton pump inhibitor omeprazole inhibits acid survival of Helicobacter pylori by a urease-independent mechanism.","volume":"107","author":"C McGowan","year":"1994","journal-title":"Gastroenterology."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"888-9","DOI":"10.1007\/BF01963775","article-title":"Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents.","volume":"8","author":"M Grayson","year":"1989","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"7235-40","DOI":"10.1073\/pnas.0702300104","article-title":"Gene expression in vivo shows that Helicobacter pylori colonizes an acidic niche on the gastric surface.","volume":"104","author":"D Scott","year":"2007","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"886-900","DOI":"10.1016\/S0016-5085(96)70056-2","article-title":"The effect of environmental pH on the proton motive force of Helicobacter pylori.","volume":"111","author":"K Meyer-Rosberg","year":"1996","journal-title":"Gastroenterology."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"729-38","DOI":"10.1128\/JB.187.2.729-738.2005","article-title":"The periplasmic alpha-carbonic anhydrase activity of Helicobacter pylori is essential for acid acclimation.","volume":"187","author":"E Marcus","year":"2005","journal-title":"J Bacteriol."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"1309-20","DOI":"10.1046\/j.1365-2958.2003.03633.x","article-title":"GadE (YhiE) activates glutamate decarboxylase-dependent acid resistance in Escherichia coli K-12.","volume":"49","author":"Z Ma","year":"2003","journal-title":"Mol Microbiol."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"470-7","DOI":"10.1128\/IAI.68.2.470-477.2000","article-title":"Expression of the Helicobacter pylori ureI gene is required for acidic pH activation of cytoplasmic urease.","volume":"68","author":"D Scott","year":"2000","journal-title":"Infect Immun."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"482-5","DOI":"10.1126\/science.287.5452.482","article-title":"A H+-gated urea channel: the link between Helicobacter pylori urease and gastric colonization.","volume":"287","author":"D Weeks","year":"2000","journal-title":"Science."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"972-9","DOI":"10.1111\/apt.12059","article-title":"The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin.","volume":"36","author":"E Marcus","year":"2012","journal-title":"Aliment Pharmacol Ther."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"627-34","DOI":"10.1111\/apt.12014","article-title":"Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype.","volume":"36","author":"M Sugimoto","year":"2012","journal-title":"Aliment Pharmacol Ther."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"514-33","DOI":"10.1111\/apt.13497","article-title":"Review article: the global emergence of Helicobacter pylori antibiotic resistance.","volume":"43","author":"I Thung","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1471-230X-3-20","article-title":"Analysis of antimicrobial susceptibility and virulence factors in Helicobacter pylori clinical isolates.","volume":"3","author":"A Godoy","year":"2003","journal-title":"BMC Gastroenterol."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"1240-6","DOI":"10.3346\/jkms.2014.29.9.1240","article-title":"Clarithromycin-based standard triple therapy can still be effective for Helicobacter pylori eradication in some parts of the Korea.","volume":"29","author":"K Yoon","year":"2014","journal-title":"J Korean Med Sci."},{"key":"ref-24","first-page":"1415-8","article-title":"Variability with omeprazole-amoxicillin combinations for treatment of Helicobacter pylori infection.","volume":"90","author":"K Graham","year":"1995","journal-title":"Am J Gastroenterol."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"39-43","DOI":"10.1080\/00365529850166185","article-title":"Prolonged and profound acid inhibition is crucial in Helicobacter pylori treatment with a proton pump inhibitor combined with amoxicillin.","volume":"33","author":"S Sj\u00f6stedt","year":"1998","journal-title":"Scand J Gastroenterol."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"391-402","DOI":"10.2165\/00003088-199835050-00004","article-title":"Continuous infusion of beta-lactam antibiotics.","volume":"35","author":"A MacGowan","year":"1998","journal-title":"Clin Pharmacokinet."},{"key":"ref-27","doi-asserted-by":"crossref","first-page":"1327-8","DOI":"10.1128\/AAC.40.5.1327","article-title":"Is bactericidal activity of amoxicillin against Helicobacter pylori concentration dependent?","volume":"40","author":"P Midolo","year":"1996","journal-title":"Antimicrob Agents Chemother."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"895-905.e5","DOI":"10.1016\/j.cgh.2014.10.036","article-title":"High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection.","volume":"13","author":"J Yang","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"721-7","DOI":"10.1023\/A:1011035007591","article-title":"CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.","volume":"18","author":"T Sakai","year":"2001","journal-title":"Pharm Res."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"131-43","DOI":"10.1358\/mf.2003.25.2.723687","article-title":"Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori.","volume":"25","author":"T Furuta","year":"2003","journal-title":"Methods Find Exp Clin Pharmacol."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"227-38","DOI":"10.1592\/phco.31.3.227","article-title":"Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.","volume":"31","author":"J Yang","year":"2011","journal-title":"Pharmacotherapy."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"719-30","DOI":"10.1111\/apt.13325","article-title":"Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study.","volume":"42","author":"Y Sakurai","year":"2015","journal-title":"Aliment Pharmacol Ther."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"412-20","DOI":"10.1124\/jpet.111.185314","article-title":"Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438).","volume":"339","author":"J Shin","year":"2011","journal-title":"J Pharmacol Exp Ther."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"179-80","DOI":"10.1111\/apt.13462","article-title":"Letter: promising results of Helicobacter pylori eradication with vonoprazan-based triple therapy after failure of proton pump inhibitor-based triple therapy.","volume":"43","author":"T Inaba","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"S-740","DOI":"10.1016\/S0016-5085(14)62679-2","article-title":"Tu1056 A Phase 3, Double-Blind Study of a Triple Therapy With TAK-438, Amoxicillin, and Clarithromycin As First Line Eradication of H. pylori and a Triple Therapy With TAK-438, Amoxicillin, and Metronidazole As Second Line Eradication of H. pylori.","volume":"146","author":"K Murakami","year":"2014","journal-title":"Gastroenterology."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/5-1747\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/5-1747\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/5-1747\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T14:22:17Z","timestamp":1553264537000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/5-1747\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,19]]},"references-count":35,"URL":"https:\/\/doi.org\/10.12688\/f1000research.8598.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.9252.r15090","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.9252.r15091","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.9252.r15089","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,19]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/5-1747\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.9252.r15089, Nayoung Kim, Seoul National University Bundang Hospital, Gyeonggi Province, South Korea, 19 Jul 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-1747\/v1#referee-response-15089","order":0,"name":"referee-response-15089","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.9252.r15090, Hidekazu Suzuki, Department of Internal Medicine, Keio University, Tokyo, 160-8582, Japan, 19 Jul 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-1747\/v1#referee-response-15090","order":1,"name":"referee-response-15090","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.9252.r15091, Yoshio Yamaoka, Molecular Pathogenesis Laboratory, Michael E DeBakey VA Medical Center, Houston, TX, 77030, USA, 19 Jul 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-1747\/v1#referee-response-15091","order":2,"name":"referee-response-15091","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The authors are supported by K08DK100661 (Elizabeth A. Marcus), UCLA CDI (Elizabeth A. Marcus), USVA 2I01BX001006 (George Sachs), R01DK105156-01(George Sachs). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}